Capstone Financial Group’s Biogen BIIB Stock Holding History

Capstone Financial Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-75	Closed	-$20K	–	158
2020 Q2	$20K	Buy	+75	New	+$22.5K	0.02%	149

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Capstone Financial Group's BIIB Position: Q3 2020 in Review

Capstone Financial Group sold out of Biogen (BIIB) in Q3 2020, closing a stake of 75 shares — an estimated $20K sold.

Capstone Financial Group first reported a position in BIIB in Q2 2020 and held it in 1 quarter. The position peaked at $20K in Q2 2020. 1,051 funds tracked by Wall St. Rank hold BIIB as of Q3 2020.

Capstone Financial Group reported no remaining Biogen position as of Q3 2020 after selling out during the quarter.
Capstone Financial Group sold 75 Biogen shares in Q3 2020, an estimated $20K.
Capstone Financial Group first reported a position in Biogen in Q2 2020 and held it in 1 quarter.
Capstone Financial Group's Biogen position peaked at $20K in Q2 2020.
1,051 funds tracked by Wall St. Rank held Biogen as of Q3 2020.

Based on Capstone Financial Group's 13F filing for Q3 2020, filed 9 Oct 2020.